Selecta Biosciences, Inc. P/S ratio

P/S ratio of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Current P/S ratio of Selecta Biosciences, Inc. is 14.05 (as of December 30, 2020)
  • P/S ratio for the quarter ending December 30, 2020 was 14.05 (a -39.11% decrease compared to previous quarter)
  • Year-over-year quarterly P/S ratio decreased by -98.81%
  • Annual P/S ratio for 2020 was 14.05 (a -24.49% decrease from previous year)
  • Annual P/S ratio for 2019 was 18.6 (a -93.53% decrease from previous year)
  • Annual P/S ratio for 2018 was 287.7 (a -71.53% decrease from previous year)
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of Selecta Biosciences, Inc.

Most recent P/S ratioof SELB including historical data for past 10 years.

Interactive Chart of P/S ratio of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. P/S ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 14.05 23.07 14.05
2019 18.6 1178.28 1215.9 18.6
2018 287.7
2017 1010.4 133.98 90.24 43.14 1010.4
2016 22.43 38.17 6.69 0.0 22.43
2015 0.0 0.0 0.0
2014 0.0

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.